FY26 Results Release
Open PDF
| Stock | Alcidion Group Ltd (ALC.ASX) |
|---|---|
| Release Time | 19 Aug 2026, 8 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Alcidion Group Ltd FY26 Results Release
Key Points
- FY26 revenue of $51.6M, up 27% on prior year
- Underlying EBITDA of $6.8M, up 34% on prior year
- Signed significant contracts with key customers
- Acquisition of Kyra flow products
- Strong cash balance of $20.6M and no debt
Full Summary
Alcidion Group Ltd released its FY26 financial results, reporting a 27% increase in revenue to $51.6M and a 34% rise in Underlying EBITDA to $6.8M. The company expanded its customer base and secured major contracts with Leidos, UH Sussex NHS, North Cumbria NHS, and Gold Coast HHS. Alcidion also acquired Kyra flow products, enhancing its presence in Australia. The company expects FY27 revenue and Underlying EBITDA to exceed FY26 levels, driven by a diversified pipeline and sustained demand for its digital health solutions.
Guidance
FY27 revenue and Underlying EBITDA expected to outperform FY26
Outlook
Alcidion expects continued growth in FY27, driven by increasing demand for its digital health solutions and a strong pipeline of opportunities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In